Company Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 09:10:53 2025-07-15 am EDT			5-day change	1st Jan Change
83.48 ^EUR	-0.07%		+0.18%	-10.95%

Jul. 11	SANOFI : UBS reiterates its Buy rating	ZD
Jul. 10	Delaware Supreme Court sides with Zantac drugmakers over cancer evidence	RE

Business description: Sanofi

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:

- pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases);

- human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.

At the end of 2024, the group had 52 production sites worldwide.

In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation.

Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Number of employees: 82,878

Sales by Activity: Sanofi

Fiscal Period: December	2020	2021	2022	2023	2024
Biopharma	-	-	-	41.21B	43.95B
Consumer Healthcare	4.45B	4.52B	5.14B	5.23B	-
Pharmaceuticals Excl. Consumer Healthcare	25.8B	27.23B	31.34B	-	-
Vaccines	7.11B	7.42B	8.9B	-	-
Others	-	-	7M	-	339M

See all business segments

Geographical breakdown of sales: Sanofi

Fiscal Period: December	2020	2021	2022	2023	2024
United States	13.46B	14.38B	18.28B	18.51B	19.99B
Rest of The World	7.76B	7.85B	8.39B	13.46B	12.07B
Europe (Excluding France)	-	-	-	8.01B	7.21B
France	-	-	-	2.38B	1.81B
Europe (Excl. Russia)	9.15B	9.76B	10B	-	-
China	2.45B	2.72B	3.12B	-	-
Russia	641M	575M	674M	-	-
Brazil	836M	815M	927M	-	-
North America (Excluding United States)	-	-	-	704M	-
Japan	1.74B	1.66B	1.61B	-	-

See all geographic segments

Executive Committee: Sanofi

Manager	Title	Age	Since
Paul Hudson CEO	Chief Executive Officer	57	2019-08-31
François-Xavier Roger DFI	Director of Finance/CFO	63	2024-03-31
Madeleine Roach COO	Chief Operating Officer	41	2023-09-30
Houman Ashrafian CTO	Chief Tech/Sci/R&D Officer	50	2023-09-10
Thomas Kudsk Larsen IRC	Investor Relations Contact	51	-

See SANOFI governance

Composition of the Board of Directors: Sanofi

Director	Title	Age	Since
Fabienne Lecorvaisier BRD	Director/Board Member	62	2013-05-02
Patrick Kron BRD	Director/Board Member	71	2014-04-30
Christophe Babule BRD	Director/Board Member	59	2019-04-29
Paul Hudson BRD	Director/Board Member	57	2019-10-29
Rachel Duan BRD	Director/Board Member	55	2020-04-27
Lise Kingo BRD	Director/Board Member	63	2020-04-27
Barbara Lavernos BRD	Director/Board Member	57	2021-04-29
Yann Tran BRD	Director/Board Member	59	2021-04-30
Wolfgang Laux BRD	Director/Board Member	57	2021-03-31
Carole Ferrand BRD	Director/Board Member	54	2022-05-02

Composition of the Board of Directors

Shareholders: Sanofi

Name	Equities	%	Valuation
L'ORÉAL 7.188 %	88,670,657	7.188 %	8 557 M €
Dodge & Cox 1.825 %	22,512,304	1.825 %	2 172 M €
SANOFI 1.317 %	16,245,648	1.317 %	1 568 M €
Amundi Asset Management SASU (Investment Management) 0.4503 %	5,554,878	0.4503 %	536 M €
OFI Invest Asset Management SA 0.3048 %	3,760,272	0.3048 %	363 M €

Name	Equities	%	Valuation
Dodge & Cox 2.897 %	73,193,057	2.897 %	3 536 M €
Fisher Asset Management LLC 0.537 %	13,566,329	0.537 %	655 M €
Invesco Advisers, Inc. 0.4695 %	11,859,545	0.4695 %	573 M €
T. Rowe Price International Ltd. 0.4369 %	11,036,878	0.4369 %	533 M €
Merrill Lynch International 0.412 %	10,407,790	0.412 %	503 M €

List of SANOFI shareholders

Holdings: Sanofi

Name	Equities	%	Valuation
SANOFI 1.32%	16,245,648	1.32%	1,567,740,935 $
SANOFI INDIA LIMITED 60.4%	13,909,587	60.4%	1,034,112,001 $
SANOFI INDIA LIMITED 60.4%	13,909,587	60.4%	923,724,128 $
EUROAPI 29.6%	28,298,074	29.6%	95,866,234 $
MEIRAGTX HOLDINGS PLC 15.61%	12,197,737	15.61%	79,529,245 $
NOVAVAX, INC. 4.3%	6,880,481	4.3%	43,347,030 $
ANAPTYSBIO, INC. 2.7%	821,917	2.7%	18,246,557 $
ANAPTYSBIO, INC. 8%	1,157,926	8%	16,523,604 $
INNATE PHARMA 9.96%	8,345,387	9.96%	14,909,868 $
VICORE PHARMA HOLDING AB 6.21%	14,571,428	6.21%	11,635,285 $

Company details: Sanofi

Sanofi

46, avenue de la Grande Armée

75017, Paris

+33 1 53 77 40 00

http://www.sanofi.com

Group companies: Sanofi

Name	Category and Sector
Helvepharm AG Helvepharm AG Pharmaceuticals: MajorHealth Technology Part of Sanofi, Helvepharm AG is a Swiss company that manufactures generic drugs. The company is based in Frauenfeld, Switzerland. Helvepharm was acquired by Sanofi from DocMorris Ltd. on July 28, 2009.	Pharmaceuticals: Major
Sanofi-Aventis Holdings (Ireland) Ltd. Sanofi-Aventis Holdings (Ireland) Ltd. MiscellaneousMiscellaneous Sanofi-Aventis Holdings (Ireland) Ltd., a subsidiary of Sanofi, is an Irish company. The firm functions as an investment holding company.	Miscellaneous
Sanofi Srl Sanofi Srl Pharmaceuticals: MajorHealth Technology Sanofi SpA engages in the research, production, and distribution of pharmaceuticals. It provides solutions for the treatment of diseases in various medical fields such as cardiovascular, diabetes, oncology and blood cancers, nephrology, equivalent medicines, rare diseases, and multiple sclerosis as well as develops vaccines. The company was founded in 1973 and is headquartered in Milan, Italy.	Pharmaceuticals: Major
Sanofi Belgium NV Sanofi Belgium NV BiotechnologyHealth Technology Part of Sanofi, Sanofi Belgium NV is a Belgian company that produces and markets biological drugs. The company is based in Diegem, Belgium. The company was founded in 1998. The CEO is Johan Heylen.	Biotechnology
Rhone-Poulenc Rorer Asia Pacific Ltd.

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SANOFI	-0.04%	+0.25%	-9.62%	-16.63%	119B
ELI LILLY AND COMPANY	+0.80%	+3.42%	-15.72%	+144.53%	718B
JOHNSON & JOHNSON	-0.05%	+1.00%	+4.63%	-10.74%	377B
ABBVIE INC.	-0.48%	+2.07%	+12.47%	+27.31%	338B
NOVO NORDISK A/S	+0.06%	-1.38%	-54.41%	+6.02%	308B
ROCHE HOLDING AG	-0.02%	-0.08%	-0.46%	-22.40%	259B
NOVARTIS AG	+0.64%	-0.84%	-2.23%	+17.27%	237B
ASTRAZENECA PLC	+0.08%	+2.90%	-12.10%	-4.23%	222B
MERCK & CO., INC.	+0.37%	+3.42%	-34.51%	-10.88%	210B
AMGEN INC.	+0.60%	+1.39%	-10.22%	+20.95%	160B
Average	+0.12%	+1.07%	-12.22%	+15.12%	294.89B
Weighted average by Cap.	+0.03%	+1.47%	-12.02%	+36.35%